Prime Medicine, Inc. faces risks in the gene editing sector despite positive developments, caution advised for retail investors. Click for my PRME stock update.

PlanetDrugsDirect.com has been providing quality medications to satisfied American patients at heavily discounted prices for over twenty years.

Bristol-Myers Squibb (BMY) to announce Q4 earnings on February 6th. Analysts expect $1.47 EPS on $11.56B revenue.

Bullish option flow detected in Bristol Myers ( BMY) Squibb with 17,611 calls trading, 2.0x expected, and implied vol increasing over 1 point to 29.73%. May-25 67.5 calls and Aug-25 45 puts are the ...

To list the 10 Best Wide Moat Stocks to Invest In, we scanned through VanEck Morningstar Wide Moat ETF and some online ...

Jefferies analyst Akash Tewari maintained a Buy rating on Bristol-Myers Squibb (BMY – Research Report) on February 3 and set a price target of ...

Bristol-Myers Squibb (NYSE:BMY – Get Free Report) is expected to be issuing its quarterly earnings data before the market opens on Thursday, February 6th. Analysts expect the company to announce ...

Faced with the encroaching threats of patent expirations and generics, biopharma companies in 2024 invested 33% more in ...

Leading the elite Wall Street firm Cravath, he became a go-to adviser on mergers and acquisitions — “all the big deals that ...

Bristol Myers Squibb Co. closed 3.24% short of its 52-week high of $61.10, which the company reached on January 27th.

The company's blockbuster drug Keytruda contributed $29.48 billion in sales in 2024, but the first of its patent expirations begins in 2028.

Body-weight cycling, sometimes referred to as yo-yo dieting, may be harmful to the kidneys for people with type 1 diabetes, ...